Latest News

FDA Approves Samsung Bioepis Biosimilars Ospomyv and Xbryk
FDA Approves Samsung Bioepis Biosimilars Ospomyv and Xbryk

February 18th 2025

Ospomyv, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Xbryk, a biosimilar to Xgeva, is indicated for preventing skeletal-related events in multiple myeloma and solid tumor bone metastases.

FDA Approves Bavarian Nordic’s Chikungunya Vaccine Vimkunya
FDA Approves Bavarian Nordic’s Chikungunya Vaccine Vimkunya

February 18th 2025

Navigating Distrust: Pharma in the Age of Social Media
Navigating Distrust: Pharma in the Age of Social Media

February 18th 2025

John Arena
Launch Strategies in Uncertain Regulatory Environments

February 18th 2025

Introducing Agentic AI: Its Revolutionary Potential in Pharma

A look at the promise and opportunities from this new and advanced type of AI in transforming commercial planning and execution for life sciences companies.

 A look at the promise and opportunities from this new and advanced type of AI in transforming commercial planning and execution for life sciences companies.

Conference Coverage

View All
JPM25: Oncology Outlook for 2025
JPM25: Oncology Outlook for 2025

January 20th 2025

Stock.adobe.com
NVIDIA Announces Pharma Partnerships to Expand AI

January 15th 2025

Stock.adobe.com
Moderna Details Product Pipeline and Finances Ahead of JP Morgan Presentation

January 14th 2025

Stock.adobe.com
Biohaven Details Pipeline Update At JP Morgan Conference

January 14th 2025

Latest Videos
Podcasts

All News